Murchison L E, Bewsher P D, Chesters M I, Ferrier W R
Br J Clin Pharmacol. 1976 Apr;3(2):273-7. doi: 10.1111/j.1365-2125.1976.tb00603.x.
Twenty-one hyperthyroid patients participated in an 8-week double-blind crossover trial of propranolol and practolol, and the effecte of these drugs on the clinical and metabolic features of the disease were studied. Propranolol was marginally more effective than practolol, as measured by the hyperthyroid diagnostic index and anxiety scale. Propranolol produced a significant reduction in the serum concentration ratio of tri-iodothyronine to thyroxine, compatible with partial inhibition of peripheral deiodination of thyroxine. Adverse reactions occurred more frequently with propranolol than with practolol. In veiw of the efficacy of practoloo, further trials in hyperthyroid patients of newer beta1-adrenoceptor antagonists, preferably without partial agonist activity, are indicated.
21名甲状腺功能亢进患者参与了一项为期8周的普萘洛尔和醋丁洛尔双盲交叉试验,并研究了这些药物对该疾病临床和代谢特征的影响。通过甲状腺功能亢进诊断指数和焦虑量表测量,普萘洛尔的疗效略优于醋丁洛尔。普萘洛尔使血清三碘甲状腺原氨酸与甲状腺素的浓度比显著降低,这与甲状腺素外周脱碘的部分抑制作用相符。普萘洛尔的不良反应发生率高于醋丁洛尔。鉴于醋丁洛尔的疗效,建议对甲状腺功能亢进患者进一步试验新型β1肾上腺素能拮抗剂,最好无部分激动剂活性。